An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease. - Kumar, Rajeev; Agarwal, Pinky; Anderson, Karen; Claassen, Daniel; Dean, Marissa; Duker, Andrew; Scott, Burton; Hoehn, Benjamin; Mongan, Ann; Lin, Ping; Cahir‐McFarland, Ellen; Taylor, Lori; et al. (Movement Disorders, 2026)